Publication

Severe Asthma in Children: Lessons Learned and Future Directions

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Anne Fitzpatrick, Emory University
Language
  • English
Date
  • 2016-01-01
Publisher
  • Elsevier
Publication Version
Copyright Statement
  • © 2015 American Academy of Allergy, Asthma & Immunology.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0091-6749
Volume
  • 4
Issue
  • 1
Start Page
  • 11
End Page
  • 19
Grant/Funding Information
  • This work was supported by National Institutes of Health grant no. U10HL098103.
Abstract
  • Severe asthma in children is a complicated and heterogeneous disorder that is extremely challenging to treat. Although most children with asthma derive clinical benefit from daily administration of low-to-medium-dose inhaled corticosteroid (ICS) therapy, a small subset of children with "severe" or "refractory" asthma require high doses of ICS and even systemic corticosteroids to maintain symptom control. These children with severe asthma are at increased risk for adverse outcomes including medication-related side effects and recurrent and life-threatening exacerbations that significantly impair quality of life. This review highlights findings on severe asthma in school-age children (age 6-17 years) from the National Heart, Lung and Blood Institute's Severe Asthma Research Program (SARP) over a 10-year period, between 2001 and 2011. Although SARP has advanced knowledge of the unique clinical, biological, and molecular attributes of severe asthma in children, considerable gaps remain for which additional studies are needed.
Author Notes
  • Corresponding author: Anne M. Fitzpatrick, PhD, Children's Healthcare of Atlanta Center for Cystic Fibrosis and Airways Disease Research, 2015 Uppergate Drive, Atlanta, GA 30322.
Keywords
Research Categories
  • Health Sciences, Human Development
  • Health Sciences, General

Tools

Relations

In Collection:

Items